Unichem Laboratories Ltd.

BSE: UNICHEMLAB506690ISIN INE351A01035

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹504.05-0.30 (-0.06%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹685.95
52W low: ₹280.00
Off 52W high: -26.52%
1M return: -5.21%
3M return: +1.57%
6M return: +30.20%
1Y return: +7.14%
20D avg volume: 3,657
50 DMA: ₹528.81
200 DMA: ₹441.25

Key ratios Consolidated

Market cap: ₹3,549 Cr
Current price: ₹504.05
52W high / low: ₹685.95 / ₹280.00
Face value: ₹2.00
P/E: 10.47
P/B: 1.28
EPS (TTM): ₹48.13
Book value / share: ₹395.09
ROE: —
ROCE: 11.40%
Operating margin: —
Net margin: —
Debt / equity: 0.17
Net debt: ₹179.30 Cr
Interest cover: 10.26
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 239.9 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	640.22	632.62	575.12	521.17	578.96	526.60	587.18	533.09	462.16	446.43	431.70	434.38
	15.37	15.61	23.47	11.80	20.97	6.82	9.25	13.62	8.79	3.86	6.15	11.28
	655.59	648.23	598.59	532.97	599.93	533.42	596.43	546.71	470.95	450.29	437.85	445.65
	603.96	599.24	567.44	515.06	552.49	542.44	538.63	484.86	437.96	435.30	438.10	429.70
	255.11	190.02	184.03	174.26	193.06	217.48	275.31	175.05	210.29	208.06	197.67	193.92
	68.17	67.25	91.81	48.93	39.76	51.01	33.48	63.43	15.20	0.28	0.21	0.21
	105.57	103.31	92.85	99.27	100.13	107.42	96.47	101.74	98.81	98.49	99.42	98.11
	7.71	6.62	9.39	7.42	8.24	6.54	5.46	6.75	4.79	4.03	4.59	5.58
	30.49	29.94	30.61	31.25	31.47	31.79	29.69	30.54	28.54	28.33	27.16	27.86
	189.70	170.78	166.57	140.02	142.27	151.64	142.44	154.31	131.34	143.87	140.04	131.66
	51.63	48.99	31.15	17.91	47.44	-9.02	57.80	61.85	32.99	15.00	-0.25	15.95
	-24.26	0.00	-12.36	275.52	-58.26	0.00	0.00	0.00	0.00	0.00	-125.62	68.02
	27.37	48.99	18.79	293.43	-10.82	-9.02	57.80	61.85	32.99	15.00	-125.87	83.97
	5.15	7.52	7.88	29.14	1.07	1.45	4.83	4.00	2.50	5.74	3.44	0.02
	22.22	41.47	10.91	264.29	-11.89	-10.47	52.97	57.85	30.49	9.26	-129.31	83.99
	3.16	6.61	1.55	37.54	-1.69	-1.49	7.52	8.22	4.34	1.31	-18.37	11.93
Key metrics
	65.57	85.55	58.79	332.10	28.89	29.31	92.95	99.14	66.32	47.36	-94.12	117.41
	10.20%	13.50%	10.20%	63.70%	5.00%	5.60%	15.80%	18.60%	14.40%	10.60%	-21.80%	27.00%
	3.50%	6.60%	1.90%	50.70%	-2.10%	-2.00%	9.00%	10.90%	6.60%	2.10%	-30.00%	19.30%
	1.20%	—	1.00%	—	-0.10%	—	2.50%	—	—	—	—	—
	10.60%	20.10%	-2.10%	-2.20%	25.30%	18.00%	36.00%	22.70%	—	—	—	—
	286.90%	496.10%	-79.40%	356.90%	-139.00%	-213.10%	141.00%	-31.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,369	2,202	2,111	1,705	1,343	1,270
	66.25	63.06	35.32	31.59	38.52	47.51
	2,435	2,265	2,146	1,736	1,382	1,317
	2,286	2,174	1,992	1,741	1,519	1,294
	803.42	768.83	888.24	742.80	532.20	456.01
	276.16	231.51	175.78	0.91	1.53	1.35
	401.00	396.63	402.21	393.06	356.41	330.49
	31.14	31.59	21.03	22.66	17.31	6.11
	122.29	125.12	124.56	113.24	113.44	91.17
	667.07	600.50	580.23	546.96	481.24	450.72
	149.68	90.52	154.59	-4.06	-137.80	23.03
	238.90	201.86	0.00	-57.61	-38.57	0.00
	388.58	292.38	154.59	-61.67	-176.36	23.03
	49.69	39.54	17.07	8.81	25.86	11.09
	338.89	252.84	137.52	-70.47	-202.23	33.06
	48.86	35.91	19.53	-10.01	-28.72	4.70
Key metrics
	542.01	449.09	300.18	74.23	-45.61	120.31
	22.88%	20.40%	14.20%	4.40%	-3.40%	9.50%
	14.30%	11.50%	6.50%	-4.10%	-15.10%	2.60%
	—	11.40%	6.80%	—	—	—
	6.44%	4.30%	23.80%	26.90%	5.80%	—
	283.10%	83.90%	295.10%	65.20%	-711.70%	—
	—	-119.40	-144.38	—	—	—
	—	0.01	-0.05	—	—	—
	—	0.17	0.18	—	—	—
	—	179.30	340.39	—	—	—
	—	239.9	236.1	—	—	—
Balance sheet
	—	3,737	3,569	—	—	—
	—	2,197	2,029	—	—	—
	—	289.48	89.58	—	—	—
	—	828.58	778.81	—	—	—
	—	974.97	988.74	—	—	—
	—	94.61	139.40	—	—	—
	—	1,204	1,279	—	—	—
	—	356.63	402.55	—	—	—
	—	885.94	991.97	—	—	—
	—	468.78	429.97	—	—	—
	—	429.66	369.16	—	—	—
	—	39.12	60.81	—	—	—
	—	2,717	2,451	—	—	—
Cash flow
	—	3.64	-7.02	—	—	—
	—	192.06	-241.23	—	—	—
	—	1.86	183.76	—	—	—
	—	123.04	137.36	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	401.90	366.27	356.24	314.90	356.90	384.25	461.24	447.83	436.88	389.75	399.24	362.43
	16.85	16.72	22.22	15.03	21.40	4.25	6.05	18.93	7.08	8.77	7.04	9.94
	418.75	382.99	378.46	329.93	378.30	388.50	467.29	466.76	443.96	398.52	406.28	372.37
	416.72	375.61	376.81	345.63	382.99	390.37	415.26	404.96	400.59	377.04	395.63	371.08
	243.77	168.80	149.98	152.42	165.31	203.88	220.80	193.01	215.64	200.32	189.37	188.69
	0.50	0.17	0.23	0.23	0.47	0.12	0.18	0.18	0.21	0.28	0.21	0.21
	75.95	73.50	64.64	69.88	72.88	72.86	70.08	73.04	71.92	72.47	68.30	71.16
	1.77	1.29	4.09	2.10	3.68	1.93	1.53	2.89	1.82	1.38	1.76	2.36
	28.98	28.69	28.97	30.02	30.11	29.93	27.47	28.45	26.39	26.11	25.22	25.62
	133.17	117.69	116.80	95.19	103.63	103.73	93.32	104.28	97.29	102.13	112.88	98.00
	2.03	7.38	1.65	-15.70	-4.69	-1.87	52.03	61.80	43.37	21.48	10.65	1.29
	0.00	0.00	-12.36	275.52	-33.14	0.00	4.00	—	—	—	-125.62	68.02
	2.03	7.38	-10.71	259.82	-37.83	-1.87	56.03	61.80	43.37	21.48	-114.97	69.30
	0.54	1.85	4.68	43.71	2.10	0.02	4.81	14.91	—	—	—	—
	1.49	5.53	-15.39	216.11	-39.93	-1.85	51.22	46.89	43.37	21.48	-114.97	69.30
	0.21	0.79	-2.19	30.69	-5.67	-0.26	7.28	6.66	6.16	3.05	-16.33	9.85
Key metrics
	32.78	37.36	22.35	291.94	-4.04	29.99	85.03	93.14	71.58	48.97	-87.99	97.28
	8.20%	10.20%	6.30%	92.70%	-1.10%	7.80%	18.40%	20.80%	16.40%	12.60%	-22.00%	26.80%
	0.40%	1.50%	-4.30%	68.60%	-11.20%	-0.50%	11.10%	10.50%	9.90%	5.50%	-28.80%	19.10%
	0.10%	—	-0.20%	—	-1.30%	—	2.20%	—	—	—	—	—
	12.60%	-4.70%	-22.80%	-29.70%	-18.30%	-1.40%	15.50%	23.60%	—	—	—	—
	103.70%	398.90%	-130.00%	360.90%	-192.10%	-108.60%	144.60%	-32.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,439	1,412	1,736	1,442	1,072	942.93
	70.82	62.90	40.83	30.39	41.85	42.07
	1,510	1,475	1,777	1,473	1,114	985.00
	1,515	1,493	1,598	1,507	1,281	1,072
	714.97	671.59	829.77	716.92	500.33	434.92
	1.13	1.05	0.85	0.91	1.53	1.35
	283.97	277.22	287.51	283.14	270.86	250.79
	9.25	11.80	7.62	10.42	9.38	2.07
	116.66	119.03	108.41	105.46	105.98	83.19
	462.85	419.35	397.02	416.63	370.61	352.21
	-4.64	-17.57	178.68	-34.57	-166.43	-86.75
	263.16	226.98	4.00	-57.61	-112.66	—
	258.52	209.41	182.68	-92.18	-279.09	-86.75
	50.78	50.47	19.72	—	20.61	31.32
	207.74	158.94	162.96	-92.18	-299.70	-55.43
	29.50	22.57	23.15	-13.09	-42.57	-7.87
Key metrics
	384.43	340.24	298.71	23.70	-163.73	-1.49
	26.71%	24.10%	17.20%	1.60%	-15.30%	-0.20%
	14.43%	11.30%	9.40%	-6.40%	-27.90%	-5.90%
	—	8.00%	7.30%	—	—	—
	-12.78%	-18.60%	20.40%	34.50%	13.70%	—
	268.79%	-2.50%	276.80%	69.20%	-440.70%	—
	—	-66.00	-40.52	—	—	—
	—	0.33	0.44	—	—	—
	—	0.02	0.05	—	—	—
	—	-199.33	50.47	—	—	—
	—	245.6	225.1	—	—	—
Balance sheet
	—	3,092	3,109	—	—	—
	—	1,534	1,566	—	—	—
	—	252.67	60.58	—	—	—
	—	582.94	748.14	—	—	—
	—	592.48	584.06	—	—	—
	—	86.38	132.07	—	—	—
	—	1,182	1,256	—	—	—
	—	225.37	261.65	—	—	—
	—	314.96	519.53	—	—	—
	—	53.34	111.05	—	—	—
	—	14.22	50.24	—	—	—
	—	39.12	60.81	—	—	—
	—	2,627	2,460	—	—	—
Cash flow
	—	52.60	72.29	—	—	—
	—	207.81	-132.07	—	—	—
	—	-70.66	-4.61	—	—	—
	—	118.60	112.81	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +9.61%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -12.78%
Profit YoY (TTM): +268.79%

Consolidated

Sales CAGR 3Y: +17.91%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +6.44%
Profit YoY (TTM): +283.10%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 70.22%

Quarter	September 2026	June 2026
Promoter %	70.22%	70.22%

Holder	Type	Holding	Previous	Change
Ipca Laboratories Limited	Promoter	52.67%	52.67%	0.00%
Dr. Prakash Amrut Mody	Promoter	12.78%	12.78%	0.00%
Hdfc Small Cap Fund	Public	7.04%	7.75%	-0.71%
Anita Prakash Mody	Promoter Group	1.88%	1.88%	0.00%
Dsp Healthcare Fund	Public	1.60%	1.56%	+0.04%
Polunin Emerging Markets Small Cap Fund, Llc	Public	1.58%	—	—
Supriya Prakash Mody	Promoter Group	1.35%	1.35%	0.00%
Suparna Prakash Mody	Promoter Group	1.35%	1.35%	0.00%
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs	Public	1.06%	1.04%	+0.02%
Dr. Prakash Amrut Mody - Suparna Mody Trust (Promoter Trust )	Promoter Group	0.07%	0.07%	0.00%
Dr. Prakash Amrut Mody - Shwetambari Mody Trust (Promoter Trust)	Promoter Group	0.06%	0.06%	0.00%
Dr. Prakash Amrut Mody - Supriya Mody Trust (Promoter Trust)	Promoter Group	0.06%	0.06%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Unichem Laboratories Ltd.	3,549	504.05	10.47	11.40%	+6.44% TTM	+283.10% TTM	+7.14%

Filings & corporate actions

Recent announcements

Unaudited financial Results for Q2FY20274 Nov 2026 · Result / Financial Results
Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2026.4 Nov 2026 · Board Meeting / Outcome of Board Meeting
Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Board Meeting Intimation ....21 Oct 2026 · Board Meeting / Board Meeting
Compliance certificate under regulation 74(5) of SEBI (DP) Regulations 201813 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under regulation 30 (LODR) - USFDA Inspection at Goa formulation Facility26 Sep 2026 · Company Update / General
Notice of Closure of Trading Window24 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Disclosure u/r. 30 of SEBI (LODR) Regulations, 201519 Sep 2026 · Company Update / General
Extension of the Exercise period for the options granted and vested under Unichem Employee Stock Option Scheme 2018.11 Sep 2026 · Company Update / General
Significant increase in the volume of securities.26 Aug 2026 · Company Update / General
The Exchange has sought clarification from Unichem Laboratories Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.26 Aug 2026 · Company Update / Clarification
Disclosure of Voting Results alongwith Scrutinizer''s Report dated 12th August 2026.12 Aug 2026 · AGM/EGM / AGM
Financial Results for the quarter ended June 30, 2026, published in the newspapers on August 12, 2026.12 Aug 2026 · Company Update / Newspaper Publication
Proceedings of the 63rd Annual General Meeting.11 Aug 2026 · AGM/EGM / AGM
Pl. find enclosed financial statement of FY 2026-2027 (CFS & SFS)11 Aug 2026 · Result / Financial Results
Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026 alongwith Limited Review report by Auditors11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Disclosure u/r. 30 of SEBI (LODR), 201529 Jul 2026 · Company Update / General
Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve The Unaudited Financial ....28 Jul 2026 · Board Meeting / Board Meeting
Pl. find attached response to clarification sought on price movement10 Jul 2026 · Company Update / General
The Exchange has sought clarification from Unichem Laboratories Ltd on July 10, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....10 Jul 2026 · Company Update / Clarification
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended June 30, 20268 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimating to shareholders - Non-email cases6 Jul 2026 · Company Update / General
Issued letters to those shareholders whose email address are not registered with the Company/Depository Particeipant/ Registrar and Share Transfer Agent, Providing the web-link from where ....6 Jul 2026 · Company Update / Trading Plan under SEBI (PIT) Regulations, 2015
Newspaper publication regarding e-voting information for 63rd Annual General Meeting of the Company.6 Jul 2026 · Company Update / Newspaper Publication
Notice of 63rd AGM - 11th August 20263 Jul 2026 · AGM/EGM / AGM
Business Responsibility and Sustainability Report for FY 20263 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report FY 20263 Jul 2026 · Others / Reg. 34 (1) Annual Report
Intimation of Closure of Trading WIndow.23 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Notice issued in the newspapers on 16th June 2026 in terms of Circular No. 20/2020, 5th May 2020, issued by the Ministry of Corporate Affairs.16 Jun 2026 · Company Update / Newspaper Publication
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Equity Intelligence India Pvt Ltd12 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Equity Intelligence India Pvt Ltd12 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Annuouncement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Clarification on Significant increase in the volume of security.11 Jun 2026 · Company Update / General
The Exchange has sought clarification from Unichem Laboratories Ltd on June 11, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.11 Jun 2026 · Company Update / Clarification
Annual General Meeting of the Company will be held on Tuesday, 11th August 2026.10 Jun 2026 · AGM/EGM / AGM
Intimation of Transfer of Equity Shares to IEPF Authority in respect of unclaimed dividend for the financial year 2018-19.1 Jun 2026 · Company Update / General
Submission of advertisement published in newspapers regarding notice for transfer of equity shares and unclaimed dividends to Investor Education and Protection Fund (IEPF) Account.1 Jun 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance Report dated May 22, 2026 for the year ended March 31, 2026.27 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Financial results for quarter and year ended March 31, 2026, published in the newspaper on May 23, 2026.23 May 2026 · Company Update / Newspaper Publication
Audited Financial Results for the year ended 31st March 202622 May 2026 · Result / Financial Results
Outcome of Board Meeting22 May 2026 · Board Meeting / Outcome of Board Meeting
Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve to consider and approve ....6 May 2026 · Board Meeting / Board Meeting

Board meetings

4 Nov 2026 Board Meeting - Financial Results
11 Aug 2026 Board Meeting - Financial Results